- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07249905
Denne studien er utformet for å karakterisere sikkerheten, toleransen og anti-tumoraktiviteten til MDX2003 hos pasienter med ulike typer lymfom
En fase 1/2 klinisk studie som evaluerer MDX2003 hos deltakere med tilbakevendende, progressiv eller refraktær B-celle malignitet
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: ModeX Therapeutics, An OPKO Health Company
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
Studiesteder
-
-
Victoria
-
Richmond, Victoria, Australia, 3121
- Rekruttering
- Epworth HealthCare
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
Hovedetterforsker:
- Dr. Costas Yannakou
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Rekruttering
- Linear Clinical Research
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
Hovedetterforsker:
- Dr. Chan Cheah
-
-
-
-
-
Haifa, Israel
- Rekruttering
- Rambam Medical Center
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
Hovedetterforsker:
- Shimrit Ringelstein
-
Jerusalem, Israel, 91120
- Rekruttering
- Hadassah Medical Center
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
Hovedetterforsker:
- Shlomzion Aumann
-
Petah Tikva, Israel
- Rekruttering
- Rabin Medical Center - Beilinson Hospital
-
Hovedetterforsker:
- Ronit Gurion
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
Tel Aviv, Israel
- Rekruttering
- Tel-Aviv Sourasky Medical Center
-
Hovedetterforsker:
- Irit Avivi
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
-
-
-
-
Seville, Spania, 41013
- Rekruttering
- Virgen del Rocío University Hospital
-
Hovedetterforsker:
- Fatima de la Cruz Vicente
-
Ta kontakt med:
- ModeX Therapeutics
- Telefonnummer: +1 857-233-9936
- E-post: info@modextx.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant must be ≥ 18 years of age.
- Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma [HGBCL], primary mediastinal B-cell lymphoma [PMBCL], etc), FL, MCL, marginal zone lymphoma, transformation of indolent B-cell lymphoma, or lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinemia.
- Participant has relapsed or progressed on at least 2 prior lines of therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- All participants must have measurable disease via computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT.
- Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.
- Adequate hematologic, hepatic and renal function.
- All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent.
Exclusion Criteria:
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
- Unresolved toxicities from previous anticancer therapy.
- Primary central nervous system (CNS) lymphoma or known CNS involvement with lymphoma.
- Active medical condition requiring chronic systemic steroid use (>10 mg/day prednisone or equivalent of >140 mg over the last 14 days) or immunosuppressive therapy, within 6 months prior to the first dose of MDX2003.
- Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment.
- Participant has a history of allogenic tissue or solid organ transplant, with the exception of corneal transplants.
- Known hypersensitivity to allopurinol or rasburicase.
- Participant has a seizure disorder requiring therapy at the time of screening (such as steroids or anti-epileptics).
- Participant is not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dose Escalation- Part A
Participants with B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion. |
MDX2003 intravenous infusion |
|
Eksperimentell: Indication Optimization- Part B
Participants with select B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion. |
MDX2003 intravenous infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A only- Identify the Maximum Tolerated Dose (MTD) for expansion for further development of MDX2003
Tidsramme: 28 days
|
Maximum Tolerated Dose is determined following the evaluation of MDX2003 safety, including the incidences of dose-limiting toxicities (DLTs), MDX2003 anti-tumor activity, and MDX2003 pharmacokinetics/pharmacodynamics. |
28 days
|
|
All Study Parts: Adverse Events (AEs)
Tidsramme: Baseline until 90 days after the participant has the last dose of MDX2003
|
Incidence and severity of adverse events (AEs) and serious AEs (SAEs), including changes in clinical laboratory parameters, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria, including changes in clinical laboratory parameters. |
Baseline until 90 days after the participant has the last dose of MDX2003
|
|
Part B only- Assess the preliminary anti-lymphoma activity of MDX2003
Tidsramme: From date of enrollment until the end of treatment, up to approximately 6 months
|
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Lugano Classification. |
From date of enrollment until the end of treatment, up to approximately 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
All Study Parts: Measure of terminal half-life (t1/2) of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter t1/2 after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Measure of area under the serum concentration-time curve (AUC) of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter AUC after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Measure of time to maximum concentration (Tmax) of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter Tmax after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Measure of maximum serum concentration (Cmax) of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter Cmax after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Measure of volume of distribution (Vd) of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter Vd after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Measure of system clearance of MDX2003
Tidsramme: 6 months
|
Characterize pharmacokinetic (PK) parameter of system clearance after intravenous infusion of MDX2003. |
6 months
|
|
All Study Parts: Evaluation of MDX2003 immunogenicity
Tidsramme: 6 months
|
The presence and persistence of anti-MDX2003 antibodies. |
6 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Histiocytiske lidelser, ondartet
- Histiocytose
- Hemic og lymfatiske sykdommer
- Lymfom
- Lymfom, follikulær
- Waldenstrom makroglobulinemi
- Lymfom, B-celle, Marginal sone
- Dendritisk cellesarkom, interdigiterende
Andre studie-ID-numre
- MDX-2003-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .